"대학병원"

During the past decade, Chung-ang University Hospital conducted 139 clinical trials. In the 10-year time frame, 139 clinical trials started and 36 clinical trials were completed, i.e. on average, 25.9% percent of trials that started reached the finish line to date. In the past 5 years, 60 clinical trials started and 28 clinical trials were completed. i.e. 46.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chung-ang University Hospital" #1 sponsor was "Chung-Ang University Hosptial, Chung-Ang University College of Medicine" with 11 trials, followed by "Pfizer" with 11 trials sponsored, "Eli Lilly and Company" with 10 trials sponsored, "Hoffmann-La Roche" with 10 trials sponsored and "Gilead Sciences" with 10 trials sponsored. Other sponsors include 128 different institutions and companies that sponsored additional 83 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chung-ang University Hospital" #1 collaborator was "Chung-Ang University Hosptial, Chung-Ang University College of Medicine" with 11 trials as a collaborator, "Korean Cancer Study Group" with 5 trials as a collaborator, "Incyte Corporation" with 4 trials as a collaborator, "Seoul National University Bundang Hospital" with 4 trials as a collaborator and "Seoul National University Hospital" with 4 trials as a collaborator. Other collaborators include 142 different institutions and companies that were collaborators in the rest 121 trials.

According to Clinical.Site data, the most researched conditions in "Chung-ang University Hospital" are "Atopic Dermatitis" (10 trials), "Breast Cancer" (4 trials), "Chronic Hepatitis B" (4 trials), "Coronary Artery Disease" (4 trials) and "Crohn's Disease" (4 trials). Many other conditions were trialed in "Chung-ang University Hospital" in a lesser frequency.

Most popular intervention types in "Chung-ang University Hospital" are "Drug" (117 trials), "Device" (23 trials), "Other" (16 trials), "Biological" (12 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (35 trials), "Baricitinib" (4 trials), "Mirikizumab" (4 trials), "Lebrikizumab" (3 trials) and "Normal saline" (3 trials). Other intervention names were less common.

The vast majority of trials in "Chung-ang University Hospital" are 177 trials for "All" genders, 4 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Chung-ang University Hospital". undefined are not yet recruiting, 28 are recruiting, 17 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 100 completed trials in Chung-ang University Hospital, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Chung-ang University Hospital, 8 "Phase 1" clinical trials were conducted, 32 "Phase 2" clinical trials and 66 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 24 trials, and there were also 24 trials that are defined as “Not Applicable".